CP
SRPT icon

Corbenic Partners’s Sarepta Therapeutics SRPT Stock Holding History

Corbenic Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-164
Closed -$7K – 239
2017
Q3 		$7K Buy
+164
New +$6.55K 0.01% 174
2015
Q1 		– Sell
-344
Closed -$5K – 207
2014
Q4 		$5K Buy
+344
New +$5.83K ﹤0.01% 161

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Corbenic Partners's SRPT Position: Q4 2017 in Review

Corbenic Partners sold out of Sarepta Therapeutics (SRPT) in Q4 2017, closing a stake of 164 shares — an estimated $7K sold.

Corbenic Partners first reported a position in SRPT in Q4 2014 and held it in 2 quarters. The position peaked at $7K in Q3 2017. 254 funds tracked by Wall St. Rank hold SRPT as of Q4 2017.

  • Corbenic Partners reported no remaining Sarepta Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Corbenic Partners sold 164 Sarepta Therapeutics shares in Q4 2017, an estimated $7K.
  • Corbenic Partners first reported a position in Sarepta Therapeutics in Q4 2014 and held it in 2 quarters.
  • Corbenic Partners's Sarepta Therapeutics position peaked at $7K in Q3 2017.
  • 254 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2017.

Based on Corbenic Partners's 13F filing for Q4 2017, filed 25 Jan 2018.